Drug Trial Radar · NCT00190593
Raloxifene Use for The Heart
Last checked: Nov 19, 2026Latest source record: Jan 26, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10,000
Actual
Start
Jun 1998
Primary completion
Not stated
Study completion Nov 2005
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Sep 19, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Prevention
- Who can join
- Female only, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.
Conditions
- Cardiovascular Diseases
- Breast Neoplasms
Interventions
raloxifeneDrug
placeboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first occurrence of coronary death, non-fatal myocardial infarction (MI), or hospitalized acute coronary syndrome other than MI combined after an expected 5 to 7.5 years of follow-up.
- Time to first occurrence of invasive breast cancer after an expected 5 to 7.5 years of follow-up.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
For additonal information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician
Minneapolis, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.